Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
10,332
Total Claims
$3.3M
Drug Cost
1,540
Beneficiaries
$2,118
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 13,194 Neurology providers
-48%
Cost per patient vs peers
$2,118 vs $4,034 avg
-18%
Brand preference vs peers
7.7% vs 9.4% avg
Brand vs Generic
Brand: 796 claims · $2.7M
Generic: 9,516 claims · $541K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Valbenazine Tosylate | 58 | $509K |
| Deutetrabenazine | 62 | $391K |
| Dimethyl Fumarate | 12 | $126K |
| Teriflunomide | 26 | $120K |
| Interferon Beta-1a | 14 | $119K |
| Immun Glob G(Igg)/Gly/Iga Ov50 | 24 | $101K |
| Onabotulinumtoxina | 56 | $83K |
| Immun Glob G(Igg)-Ifas/Glycine | 19 | $72K |
| Cenobamate | 53 | $60K |
| Ubrogepant | 45 | $57K |
| Carbidopa/Levodopa | 46 | $50K |
| Immune Globul G/Gly/Iga Avg 46 | 20 | $45K |
| Erenumab-Aooe | 45 | $44K |
| Lacosamide | 13 | $39K |
| Rimegepant Sulfate | 21 | $36K |
Prescribing Profile
89
Unique Drugs
12.0
Anomaly Score
Patient Profile
73
Avg Age
61%
Female
1.45
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About